Consistent with the OS results, low expression of IL12B (HR = 0.584, 95% CI = 0.386–0.884, p = 0.0109 for the high vs. low IL12B expression female subgroup; Fig. 5A) and IL10 (HR = 0.612, 95% CI = 0.403–0.928, and p = 0.0209 for the high vs. low IL10 expression female subgroup; Fig. 3B) significantly increased the living risks of female LUAD patients before tumor recurrence. Here, IL10 is linked to neoplasm.